GSK plc (NYSE:GSK) Shares Sold by Tidal Investments LLC

Tidal Investments LLC trimmed its holdings in shares of GSK plc (NYSE:GSK) by 3.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 29,192 shares of the pharmaceutical company’s stock after selling 969 shares during the quarter. Tidal Investments LLC’s holdings in GSK were worth $1,193,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Optimist Retirement Group LLC grew its stake in GSK by 3.7% during the 3rd quarter. Optimist Retirement Group LLC now owns 49,554 shares of the pharmaceutical company’s stock valued at $2,026,000 after purchasing an additional 1,790 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of GSK during the 3rd quarter valued at approximately $787,000. World Investment Advisors LLC acquired a new stake in shares of GSK during the third quarter worth approximately $421,000. Stock Yards Bank & Trust Co. bought a new stake in shares of GSK in the third quarter worth $210,000. Finally, Second Line Capital LLC acquired a new stake in GSK in the third quarter valued at $245,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 19.97 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.00% of the company’s stock.

GSK Trading Down 1.6 %

Shares of NYSE GSK opened at $33.69 on Thursday. GSK plc has a 12-month low of $32.83 and a 12-month high of $45.92. The company has a market cap of $69.82 billion, a price-to-earnings ratio of 21.88, a price-to-earnings-growth ratio of 1.54 and a beta of 0.64. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock’s 50 day simple moving average is $35.87 and its 200 day simple moving average is $39.03.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.66%. GSK’s payout ratio is 98.70%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and reduced their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 12th. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.